167 related articles for article (PubMed ID: 31182914)
1. Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer.
Wang H; Huang F; Zhang Z; Wang P; Luo Y; Li H; Li N; Wang J; Zhou J; Wang Y; Li S
Int J Biol Sci; 2019; 15(5):929-941. PubMed ID: 31182914
[TBL] [Abstract][Full Text] [Related]
2. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
Bago R; Sommer E; Castel P; Crafter C; Bailey FP; Shpiro N; Baselga J; Cross D; Eyers PA; Alessi DR
EMBO J; 2016 Sep; 35(17):1902-22. PubMed ID: 27481935
[TBL] [Abstract][Full Text] [Related]
3. MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.
Wang Y; Zhang M; Wang Z; Guo W; Yang D
Mol Carcinog; 2020 Oct; 59(10):1188-1198. PubMed ID: 32810332
[TBL] [Abstract][Full Text] [Related]
4. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
[TBL] [Abstract][Full Text] [Related]
5. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
[TBL] [Abstract][Full Text] [Related]
6. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44.
Malik N; Nirujogi RS; Peltier J; Macartney T; Wightman M; Prescott AR; Gourlay R; Trost M; Alessi DR; Karapetsas A
Biochem J; 2019 Oct; 476(20):3081-3107. PubMed ID: 31665227
[TBL] [Abstract][Full Text] [Related]
8. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
10. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall BA; Kim TY; Skor MN; Conzen SD
Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
[TBL] [Abstract][Full Text] [Related]
11. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas.
Grzmil M; Huber RM; Hess D; Frank S; Hynx D; Moncayo G; Klein D; Merlo A; Hemmings BA
J Clin Invest; 2014 Feb; 124(2):742-54. PubMed ID: 24401275
[TBL] [Abstract][Full Text] [Related]
12. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
13. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
14. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways.
Chen XG; Liu F; Song XF; Wang ZH; Dong ZQ; Hu ZQ; Lan RZ; Guan W; Zhou TG; Xu XM; Lei H; Ye ZQ; Peng EJ; Du LH; Zhuang QY
Mol Carcinog; 2010 Jun; 49(6):603-10. PubMed ID: 20512842
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting 4EBP1 in Glioblastoma.
Fan QW; Nicolaides TP; Weiss WA
Clin Cancer Res; 2018 Jan; 24(1):14-21. PubMed ID: 28696243
[TBL] [Abstract][Full Text] [Related]
19. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
20. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]